<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <title>modification_summary_b_031.html</title>
</head>
<body>
<p>* A follow-on public stock offering was completed.</p>
<p>* The company issued a large amount of convertible senior notes.</p>
<p>* The Lithobid and Vancocin branded products were acquired.</p>
<p>* New development collaborations were started with two pharmaceutical companies.</p>
<p>* A new generic product, Methazolamide tablets, was launched.</p>
<p>* The company filed a new drug application for an anti-cancer drug.</p>
<p>* A major competitor for a key generic product re-entered the market.</p>
<p>* New charges related to price protection obligations were disclosed.</p>
<p>* Royalties from a newly acquired product became a new revenue source.</p>
<p>* A new risk was disclosed concerning DEA quota approval for Opium Tincture.</p>
<p>* Minimum purchase commitments for raw materials substantially increased.</p>
<p>* SG&amp;A expense drivers shifted from merger costs to public company costs.</p>
<p>* An expectation of future profitability drove a tax valuation allowance reversal.</p>
<p>* An obligation to pay investor monitoring fees was terminated.</p>
<p>* The company now generates positive cash from operations.</p>
<p>* The disclosure no longer states the company has never generated positive operating cash flow.</p>
<p>* A new strategic focus on expanding through product and company acquisitions is stated.</p>
<p>* The company acquired intellectual property rights for two new products, Lithobid and Vancocin.</p>
<p>* The company issued a significant amount of new convertible senior notes.</p>
<p>* A follow-on public offering of common stock was completed.</p>
<p>* The company entered into new bond hedge and warrant transactions.</p>
<p>* Revenue concentration from the company&#x27;s top product, EEMT, has increased.</p>
<p>* Medicaid rebates are newly identified as a critical accounting estimate.</p>
<p>* The aggregate accrual rate for sales deductions decreased.</p>
<p>* Cash flow from investing activities shifted from a source to a significant use.</p>
<p>* A new disclosure for estimating Medicaid rebates was added.</p>
<p>* Intangible assets disclosure now specifies rights for Lithobid and Vancocin products.</p>
<p>* An affirmative statement of no impairment indicators for intangible assets was added.</p>
<p>* Stock-based compensation is now allocated to COGS and R&amp;D, not just SG&amp;A.</p>
<p>* A disclosure about stock options pending shareholder approval has been removed.</p>
<p>* Disclosures for new accounting standards on revenue recognition and going concern were introduced.</p>
</body>
</html>
